GenePeeks names new chair
This article was originally published in Scrip
Lifeprint Group, the parent company for GenePeeks – a genetic information company focused on next-generation disease risk analysis – has named Mara Aspinall executive chair of its board of directors. Ms Aspinall is the former president and CEO of Ventana Medical Systems. Vertana is a member of the Roche Group and a leader in the development, manufacture and commercialization of tissue-based cancer diagnostics that enable the delivery of personalized healthcare to patients. Previously, Ms Aspinall spent 12 years with Genzyme, where she held leadership roles that included president of Genzyme Genetics and president of Genzyme Pharmaceuticals.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.